Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction

Autor: christine marie, Mossiat C, Jm, Lecomte, Jc, Schwartz, Bralet J

Publikováno v: Europe PubMed Central

The aim of the present study was to determine, in rats with myocardial infarction, the systemic and cardiac hemodynamic effects of aladotrilat and of its prodrug, aladotril, both of which display inhibitory activity toward both neutral endopeptidase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9b54161a4a476b4be215c314a99a6821
https://pubmed.ncbi.nlm.nih.gov/8531099

Modulation of pentagastrin-induced histamine release by histamine H3 receptors in the anaesthetized dog

Autor: A. Rouleau, Luigi Intorre, Garbarg M, Jc Schwartz, Giulio Soldani, Simone Bertini

Publikováno v: Pharmacological Research. 31:11

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc3a17f77689061de299ced2b773c6d1
https://doi.org/10.1016/1043-6618(95)86305-2

Pharmacological properties of acetorphan, a parenterally active 'enkephalinase' inhibitor

Autor: Jm, Lecomte, Costentin J, Vlaiculescu A, Chaillet P, Marcais-Collado H, Llorens-Cortes C, Marion LEBOYER, Jc, Schwartz

Publikováno v: Europe PubMed Central

Acetorphan, i.e. N-[(R,S)-3-acetylmercapto-2-benzylpropanoyl]-glycine, benzyl ester, is a lipophilic derivative of Thiorphan, a potent inhibitor of "enkephalinase" (EC 3.4.24.11). On purified enkephalinase its inhibitory potency was approximately 100

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d3c6dd3ae6f2926e08b8105b8ffb5029
https://pubmed.ncbi.nlm.nih.gov/3519939

Les transmissions histaminergiques cérébrales

Autor: JC Schwartz, M Garbarg, Hélène Pollard, JM Arrang

Publikováno v: médecine/sciences. 2:10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b12dac05004220f1c54fbb6485abb88
https://doi.org/10.4267/10608/3408

Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.

Autor: Dauvilliers Y; Centre National de Référence Narcolepsie, Unité du Sommeil, CHU Montpellier, Hôpital Gui-de-Chauliac, Service de Neurologie, Université de Montpellier, INSERM INM, Montpellier, France., Craig SE; Liverpool Sleep and Ventilation Centre, University Hospital Aintree, Liverpool University Foundation Trust, Liverpool, UK., Bonsignore MR; PROMISE Department, University of Palermo, Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo, Italy., Barbé F; Respiratory Department, Institut Ricerca Biomedica de Vilanova, Lleida, Spain., Verbraecken J; Multidisciplinary Sleep Disorders Centre, Antwerp University Hospital and University of Antwerp, Edegem-Antwerp, Belgium., Asin J; Department of Pulmonary Medicine, Centre for Sleep Medicine, Amphia Hospital, Breda, The Netherlands., Georgiev O; Department of Internal Medicine, Pulmonology, Alexandrovska Hospital Medical University, Sofia, Bulgaria., Tiholov R; Department of Internal Diseases, Sv. Ivan Rilski Multiprofile Hospital for Active Treatment, Kozloduy, Bulgaria., Caussé C; Bioprojet Pharma, Paris, France., Lecomte JM; Bioprojet Pharma, Paris, France., Schwartz JC; Bioprojet Pharma, Paris, France., Lehert P; Faculty of Economics, University Louvain, Ottignies-Louvain-la-Neuve, Belgium.; Faculty of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Randerath W; Bethanien Hospital, Institute of Pneumonology, University of Cologne, Solingen, Germany., Pépin JL; HP2 Laboratory INSERM U1300, University Grenoble Alpes, Grenoble, France.

Publikováno v: Journal of sleep research [J Sleep Res] 2024 Oct 08, pp. e14373. Date of Electronic Publication: 2024 Oct 08.